William F. Hickey

William F. Hickey

Auto-generated profile, based on publicly available information

William F. Hickey

Medical Affairs (HIV), MSD (UK) Limited, London, UK

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 1993 in Glia
Verified
Journal Article
Closed access
PDF file
HLHans Lassmann
Hans Lassmann
MSMascha Schmied
Mascha Schmied
KVKarl Vass
Karl Vass
WHWilliam F. Hickey
William F. Hickey

1 May 2006 in Journal of Neuropathology & Experimental Neurology
Verified
Journal Article
Open access
PDF file
MMMarcus Müller
Marcus Müller
MSMarkus Stenner
Markus Stenner
KWKarin Wacker
Karin Wacker
ERErich B. Ringelstein
Erich B. Ringelstein
WHWilliam F. Hickey
William F. Hickey
RKReinhard Kiefer
Reinhard Kiefer
Macrophages are intimately involved in the pathogenesis of inflammatory neuropathies. The contribution of resident endoneurial macrophages is unknown since their differentiation from infiltrating macrophages is difficult due to missing cellular markers. Previous studies demonstrated the participation of resident macrophages in Wallerian degeneration and the pathogenesis of hereditary neuropathies. The question arises whether resident macrophages are involved in experimental autoimmune neuritis (EAN) where they could contribute to immunosurveillance and antigen presentation. To address this question we used bone marrow chimeric rats, allowing the differentiation between resident and hematogenous cells. Immunohistochemistry and in situ hybridization were applied on to identify and characterize resident macrophages in terms of morphological features, expression of activation markers, proliferation, phagocytosis, and MHC-II expression. Endoneurial macrophages of resident origin were detectable at all stages of disease with a contribution of at least 27% of the total macrophages. They appeared activated by morphological and immunohistochemical criteria and proliferated early. MHC-II-positive resident macrophages were observed that had phagocytosed myelin. These results demonstrate that the macrophage response in EAN is partly of intrinsic origin. The rapid activation and proliferation of resident endoneurial macrophages points toward an active role of these cells in inflammatory peripheral nerve disease, especially early in disease.

26 July 2004 in Journal of Leukocyte Biology
Verified
Journal Article
Open access
PDF file
TDTodd S. Davidson
Todd S. Davidson
WHWilliam F. Hickey
William F. Hickey
Antisecretory factor (ASF) was originally identified as a potent inhibitor of intestinal fluid secretion induced by a number of enterotoxins. In addition to its involvement in intestinal fluid secretion, ASF modulates the proliferation of memory/effector T cells and is expressed by cells of the immune system. This report describes the role of ASF in modulating immune responses and assesses the regulation of ASF during an in vivo immunological reaction. ASF expression was redistributed during adoptively transferred experimental autoimmune encephalomyelitis (EAE), and in response to other inflammatory stimuli. Administration of the anti-ASF antibody TLD-1A8A increased the clinical severity and duration of the disease. Consistent with these findings, addition of TLD-1A8A to T cell proliferation assays resulted in up-regulation of the proinflammatory cytokines IL-18 and IL-6 and in down-regulation of IL-10. Furthermore, we identified cytokines that regulated the expression of ASF at both the mRNA and protein level. ASF, therefore, appears to play a previously unappreciated and potentially important role in the regulation of immune responses.

1 June 2005 in Alcohol, Clinical and Experimental Research
Verified
Journal Article
Closed access
PDF file
PSPeter J. Syapin
Peter J. Syapin
WHWilliam F. Hickey
William F. Hickey
CKCynthia J.M. Kane
Cynthia J.M. Kane

16 November 2023 in International Journal of STD & AIDS
Verified
Journal Article
Closed access
COCharlotte O’hAlloran
Charlotte O’hAlloran
YGYvonne Gilleece
Yvonne Gilleece
SLSuki Leung
Suki Leung
VCVeronica Canuto
Veronica Canuto
CMConnor McAlpine
Connor McAlpine
AMAna Milinkovic
Ana Milinkovic
Background: Doravirine is a non-nucleoside reverse transcriptase inhibitor recommended for the treatment of virologically suppressed and treatment naïve people living with HIV. The DRIVE-REAL study aimed to describe the characteristics, treatment patterns, and virological outcomes of doravirine users in a real-world cohort in the UK. Methods: A retrospective, observational, multi-centre chart review was conducted for 300 adults living with HIV initiating doravirine-containing antiretroviral therapy. Results: At baseline 83% of individuals were male, 45% aged ≥50 years, 65% white ethnicity. Median time since HIV diagnosis was 12 years. 96% were antiretroviral therapy-experienced, 87% had a HIV viral load <50 copies/ml, and 15% had resistance to at least one antiretroviral drug. 66% had comorbidities, most commonly depression (26%), and 70% were taking at least one co-medication. At six months, 94% ( n = 283/300) were still receiving doravirine. Viral load data were available for n = 266/300 individuals and 95% ( n = 253/266) had viral load <50 copies/ml. Conclusions: Individuals initiating doravirine in this cohort are predominantly treatment-experienced white middle-aged males, with a high frequency of comorbidities and co-medication. The majority of individuals at 6 months remained on doravirine and maintained or achieved HIV viral suppression. This study provides epidemiologic characteristics that can inform clinical care and subsequent hypothesis-testing studies.

5 April 2016 in Neurology
Verified
Journal Article
Closed access
DKDiviya Kaul
Diviya Kaul
KMKeith Morley
Keith Morley
MPMarius Pakalniskis
Marius Pakalniskis
WHWilliam Hickey
William Hickey
SLStephen Lee
Stephen Lee